Symbicort Onset of Action 2 | NCT00646009

Studies
Symbicort Onset of Action 2

NCT00646009

Sponsor

AstraZeneca

Status

Completed

Last Update Posted

Jan 24, 2011Estimated

Enrollment

48Estimated

Phase

Phase 3

Conditions

Asthma

Interventions

budesonide/formoterol
fluticasone/salmeterol
albuterol

Countries

Not provided

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

ID	Type	Description	Link
D5896C00733

Status Module

Record Verification Date

Jan 2011

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Mar 2003

Primary Completion Date

Not provided

Completion Date

Aug 2003Actual

First Submitted Date

Mar 26, 2008

First Submission Date that Met QC Criteria

Mar 26, 2008

First Posted Date

Mar 28, 2008Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 21, 2011

Last Update Posted Date

Jan 24, 2011Estimated

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 3

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

48Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
1	Experimental	budesonide/formoterol	Drug: budesonide/formoterol
2	Active Comparator	fluticasone/salmeterol	Drug: fluticasone/salmeterol
3	Active Comparator	albuterol	Drug: albuterol

Interventions

Name	Type	Description	Arm Group Labels	Other Names
budesonide/formoterol	Drug		1	Symbicort
fluticasone/salmeterol

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
FEV1 3 minutes post dose		4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)

Secondary Outcomes

Measure	Description	Time Frame
12 hour serial FEV1		4 assessments across 4 visits whilst on treatment (visits may be between 3 and 14 days apart)
Patients perception of effect		Patients perception of effect

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

At least 18 years of age
Diagnosis of asthma and baseline lung function test results as determined by the protocol
Required and received inhaled corticosteroids within timeframe and doses specified in the protocol

Exclusion Criteria:

Severe asthma or asthma that is markedly effected by seasonal factors
Has required and received non-inhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Name	Affiliation	Role
Catherine Bonuccelli	AstraZeneca	Study Director

Condition Browse Module

MeSH Terms

ID	Term
D001249	Asthma

Ancestor Terms

ID	Term
D001982	Bronchial Diseases
D012140	Respiratory Tract Diseases
D008173	Lung Diseases, Obstructive
D008171	Lung Diseases

Browse Leaves

Not provided

Browse Branches

Not provided

Intervention Browse Module

MeSH Terms

ID	Term
D000069502	Budesonide, Formoterol Fumarate Drug Combination
D000068297	Fluticasone-Salmeterol Drug Combination
D000420	Albuterol

Ancestor Terms

ID	Term
D000068759	Formoterol Fumarate
D004983	Ethanolamines
D000605	Amino Alcohols
D000438	Alcohols

Browse Leaves

Not provided

Browse Branches

Not provided